Skip to main content

Table 4 Results of immunohistochemical stainings

From: Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

Scoring

HER1 (n = 48)

HER3 (n = 47)

HER4 (n = 48)

phospho-HER2 (n = 43)

p27Kip1 (n = 48)

ERα (n = 45)

PR (n = 46)

0

37 (77.1)

8 (16.7)

22 (45.8)

36 (83.7)

n/a

n/a

n/a

1

7 (14.6)

31 (64.6)

7 (14.6)

3 (7.0)

n/a

n/a

n/a

2

3 (6.2)

8 (16.7)

12 (25.0)

4 (9.3)

n/a

n/a

n/a

3

1 (2.1)

0

7 (14.6)

0

n/a

n/a

n/a

Negative

37 (77.1)

8 (16.7)

22 (45.8)

36 (83.7)

24 (50.0)

19 (42.2)

29 (63.0)

Positive

11 (22.9)

39 (81.2)

26 (54.2)

7 (16.3)

24 (50.0)

26 (57.8)

17 (37.0)

  1. All 48 patients were HER2 FISH positive (ratio > 1.5). Numbers in parentheses are percentages. Results in bold define data considered positive for immunohistochemistry. n/a = not applicable, scoring defined in methodical chapter.
  2. ER = oestrogen receptor; HER = human epidermal growth factor receptor; PR = Progesterone receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us